Login to Your Account

Myeloid bid draws $62M series B round for Pionyr, headed to clinic

By Randy Osborne
Staff Writer

Wednesday, December 13, 2017

With $62 million in series B cash, Pionyr Immunotherapeutics Inc. hopes to "get initial human readouts in a couple of programs – at least one, maybe a second," CEO Steven James told BioWorld. The company is advancing its Myeloid Tuning technology.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription